World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

John G. McHutchison net worth and biography

John McHutchison Biography and Net Worth

CEO of Assembly Biosciences

Dr. McHutchison joined Assembly as Chief Executive Officer and President in 2019 and was also appointed as a Director. He most recently served as Chief Scientific Officer and Head of Research and Development at Gilead Sciences. During his nine years at Gilead he led the organization in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas including the curative treatment regimens for chronic hepatitis C (HCV), and treatment of chronic HBV. Prior to Gilead, Dr. McHutchison held numerous positions at Duke University Medical Center, including Associate Director of the Duke Clinical Research Institute, Professor of Medicine in the Division of Gastroenterology, Director at Duke Clinical Research Unit and Co-Director of the Duke Clinical and Translational Science Award. Earlier in his career, Dr. McHutchison spent nearly a decade at Scripps Clinic and Research Foundation, and was previously an Assistant Professor of Medicine at the University of Southern California in Los Angeles. Dr. McHutchison received his degrees in medicine and surgery from the University of Melbourne in Australia, completed an internal medicine residency and gastroenterology fellowship at the Royal Melbourne Hospital, and a post-doctoral fellowship in Liver Diseases at the University of Southern California. He is a member of the Royal Australasian College of Physicians, and in 2018, he was appointed an Officer of the Order of Australia (AO).

What is John G. McHutchison's net worth?: The estimated net worth of John G. McHutchison is at least $283,512.56 as of April 1st, 2024. Dr. McHutchison owns 21,221 shares of Assembly Biosciences stock worth more than $283,513 as of April 25th. This net worth estimate does not reflect any other investments that Dr. McHutchison may own. Learn More about John G. McHutchison's net worth.
How do I contact John G. McHutchison?: The corporate mailing address for Dr. McHutchison and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on John G. McHutchison's contact information.
Has John G. McHutchison been buying or selling shares of Assembly Biosciences?: In the last ninety days, John G. McHutchison has sold $15,762.42 in Assembly Biosciences stock. Most recently, John G. Mchutchison sold 1,206 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $13.07, for a transaction totalling $15,762.42. Following the completion of the sale, the director now directly owns 21,221 shares of the company's stock, valued at $277,358.47. Learn More on John G. McHutchison's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes William Delaney (Insider), John McHutchison (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.
Are insiders buying or selling shares of Assembly Biosciences?: During the last twelve months, Assembly Biosciences insiders bought shares 1 times. They purchased a total of 24,999 shares worth more than $233,990.64. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 5,221 shares worth more than $65,307.18. The most recent insider tranaction occured on April, 1st when Director John G Mchutchison sold 1,206 shares worth more than $15,762.42. Insiders at Assembly Biosciences own 4.1% of the company. Learn More about insider trades at Assembly Biosciences.
Information on this page was last updated on 4/1/2024.

John G. McHutchison Insider Trading History at Assembly Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	1,206	$13.07	$15,762.42	21,221
5/23/2023	Sell	2,164	$12.48	$27,006.72	14,096
3/30/2023	Sell	1,240	$9.84	$12,201.60	14,802
8/8/2022	Sell	1,026	$25.56	$26,224.56	16,042
3/30/2022	Sell	384	$26.04	$9,999.36
8/9/2021	Sell	1,013	$43.20	$43,761.60

John G. McHutchison Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $13.36

$12.98

$13.38

50 Day Range

MA: $13.01

$11.11

$15.06

2 Week Range

Now: $13.36

$7.69

$20.04

Volume

6,103 shs

Average Volume

26,928 shs

Market Capitalization

$73.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Click here to find out what to do.